亚太地区前列腺癌核医学市场预测至 2028 年 – COVID-19 影响和区域分析 – 按类型（PET 和 SPECT）、PET 产品（F-18、C-11 和 Ga68-PSMA）和结束用户（医院、诊所等）
No. of Pages: 120 | Report Code: BMIRE00025670 | Category: Life Sciences
No. of Pages: 120 | Report Code: BMIRE00025670 | Category: Life Sciences
亚太前列腺癌核医学市场预计将从2022年的1.561亿美元增长到2028年的2.9537亿美元；预计2022年至2028年复合年增长率为11.2%。
核医学主要用于诊断心血管疾病和癌症。由于核医学行业已经饱和，许多公司和利益相关者都将重点放在扩大放射性药物的总体用途上。随着应用领域的扩大，放射性药物的需求和使用量预计将增加，这将有助于企业在未来几年扩大其产品线和神经系统应用的市场份额。PET 是一种无创核成像方法，用于癌症诊断、分期、和治疗监测。 PET 成像是通过将正电子标记的放射性药物注射到患者体内来完成的，通常是静脉注射。精确成像可以帮助医生在个体化癌症治疗时代提供更好的治疗。现代成像的使用正在不断增长，因为它有助于准确的局部分期和早期转移性癌症发现、准确的寡转移性疾病识别和最佳治疗反应评估。新一代成像模式，例如全身 MRI 和 PET 与 CT 组合的分子成像以及采用创新放射性药物的 PET 和 MRI 组合，为晚期前列腺癌患者提供了新的成像选择。
借助新功能和技术，供应商可以吸引新客户并扩大其在新兴市场的足迹。这一因素可能会推动亚太地区前列腺癌核医学市场。预计亚太地区前列腺癌核医学市场在预测期内将以良好的复合年增长率增长。
亚太地区前列腺癌核医学市场收入及预测至 2028 年（美国）百万美元
）
亚太地区前列腺癌核医学市场细分
亚太地区前列腺癌核医学市场按类型、PET 产品、最终用户和国家/地区进行细分。根据类型，亚太地区前列腺癌核医学市场分为 PET 和 SPECT。 2022年，PET在亚太地区前列腺癌核医学市场占据主导地位。根据PET产品，亚太地区前列腺癌核医学市场分为F-18、C-11和Ga68-PSMA。 2022 年，F-18 细分市场将主导亚太地区前列腺癌核医学市场。根据最终用户，亚太地区前列腺癌核医学市场分为医院、诊所和其他。 2022年，医院细分市场在亚太地区前列腺癌核医学市场中占据主导地位。根据国家/地区，亚太地区前列腺癌核医学市场分为中国、日本、印度、韩国、澳大利亚和亚太地区其他地区。 2022 年，中国市场在亚太地区前列腺癌核医学市场占据主导地位。
ImaginAb;锔;欢欣鼓舞的放射制药公司； ABX 高级生化化合物有限公司； Telix 制药有限公司；诺华公司； Altair 旗下的 Lantheus Medical Imaging, Inc. 和 Lantheus Medical Imaging, Inc. 是亚太地区前列腺癌核医学市场的领先公司之一。
Strategic insights for Asia Pacific Prostate Cancer Nuclear Medicine involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.
| Report Attribute | Details |
|---|---|
| Market size in 2022 | US$ 156.10 Million |
| Market Size by 2028 | US$ 295.37 Million |
| Global CAGR (2022 - 2028) | 11.2% |
| Historical Data | 2020-2021 |
| Forecast period | 2023-2028 |
| Segments Covered |
By 类型
|
| Regions and Countries Covered | 亚太地区
|
| Market leaders and key company profiles |
The regional scope of Asia Pacific Prostate Cancer Nuclear Medicine refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.
The Asia Pacific Prostate Cancer Nuclear Medicine Market is valued at US$ 156.10 Million in 2022, it is projected to reach US$ 295.37 Million by 2028.
As per our report Asia Pacific Prostate Cancer Nuclear Medicine Market, the market size is valued at US$ 156.10 Million in 2022, projecting it to reach US$ 295.37 Million by 2028. This translates to a CAGR of approximately 11.2% during the forecast period.
The Asia Pacific Prostate Cancer Nuclear Medicine Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Asia Pacific Prostate Cancer Nuclear Medicine Market report:
The Asia Pacific Prostate Cancer Nuclear Medicine Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Asia Pacific Prostate Cancer Nuclear Medicine Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Asia Pacific Prostate Cancer Nuclear Medicine Market value chain can benefit from the information contained in a comprehensive market report.
Office No. 1011, First floor, Farena Corporate Park, Magarpatta-Mundhwa road, Pune - 411028, Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For Asia Pacific Prostate Cancer Nuclear Medicine Market
